Innoviva EV/EBIT INVA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026: 7.2×
10-year median: 6.5×
Against its 10-year history: 63rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.9× to 23.7×
Peer median: 9.0×

Innoviva's EV/EBIT is 7.2× as of Oct 23, 2026.

That is above its ten-year median of 6.5×, close to the middle of its last ten years.

Over that time it ranged from 1.9× in Feb 2023 to 23.7× in Oct 2016.

The median for 10 large drugmakers of a similar size is 9.0×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.2×	7.0×	9.2×
2025	7.2×	5.9×	8.3×
2024	6.7×	5.5×	15.5×
2023	15.1×	1.9×	15.3×
2022	2.1×	2.0×	4.9×
2021	4.3×	3.7×	4.8×
2020	3.9×	3.2×	6.5×
2019	6.2×	4.9×	10.3×
2018	9.0×	8.5×	14.3×
2017	12.5×	11.4×	21.2×
2016	19.6×	18.3×	137×
2015	123×	109×	123×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

Company	EV/EBIT
INVAInnoviva	7.2×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	7.6×
PAHCPhibro Animal Health	11.7×
ANIPANI Pharmaceuticals	10.5×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	12.2×
HRMYHarmony Biosciences	6.9×
PBHPrestige Consumer Healthcare	14.5×
ABUSArbutus Biopharma	4.9×
NRIXNurix Therapeutics	7.1×
Peer median	9.0×

Where Innoviva ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Innoviva

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.